期刊文献+

莫西沙星对慢阻肺心功能失代偿期患者QT离散度的影响 被引量:7

Effect of moxifloxacin on QT dispersion of cor pulmonale patients with decompensation
下载PDF
导出
摘要 目的观察莫西沙星对肺心病失代偿患者QT离散度的影响。方法将60例使用莫西沙星患者分成两组,一组为肺心病失代偿患者,另一组为非肺心病失代偿患者,予以莫西沙星抗感染治疗,记录患者QT离散度并进行分析。结果 30例肺心病失代偿患者予以莫西沙星抗感染治疗,用药2小时和用药48小时分别与用药前QTd比较有显著统计学意义(P<0.05),用药2小时与用药48小时QTd比较有显著统计学意义(P<0.05);30例非肺心病失代偿患者予以莫西沙星抗感染治疗,用药2小时与用药前QTd比较无显著统计学意义(P>0.05),用药48小时与用药前QTd比较有显著统计学意义(P<0.05)。结论莫西沙星可以增加QTd的作用,尤其对有肺心病等潜在QT间期延长的患者,应警惕QTd增大延长不良反应的发生。 Objective To investigate the effect of moxifloxacin on QT dispersion of cor pulmonale patients with decompensation.Methods 60 patients were randomly divided into two groups: the decompensation group and the non-decompensation group.All patients were treated with moxifloxacin and their QT dispersion were recorded and analyzed.Results The difference of QT dispersion showed a statistical significance before and 2 and 48 hours after the treatment in the decompensation group(P0.05).There was no significant difference before and 2-hour after the treatment in the non-decompensation group(P0.05),but it showed statistical significance before and 48-hour after the treatment in the non-decompensation group(P0.05).Conclusion Moxifloxacin can prolong the effect of QT dispersion,especially for those cor pulmonale patients with decompensation.The adverse reactions caused by the prolongation of QT dispersion should be paid more more attention.
作者 晋小祥 刘燕
出处 《临床肺科杂志》 2013年第5期830-831,共2页 Journal of Clinical Pulmonary Medicine
关键词 QT离散度 肺心病 莫西沙星 QT decompensation cor pulmonale moxifloxacin
  • 相关文献

参考文献8

二级参考文献59

共引文献34

同被引文献64

  • 1许瑞凌,彭建春,汪瑾.珍菊降压片致严重电解质紊乱并误诊1例[J].医药导报,2007,26(6):686-686. 被引量:6
  • 2史红耀,黄仲义,黄毅慧,范英,沈麦琪,仇益群.吉米沙星与左氧氟沙星治疗下呼吸道感染的随机对照比较[J].中国新药与临床杂志,2007,26(9):678-680. 被引量:7
  • 3郭庆兰,阚丽娅,刘德梦,等.住院病例抗菌药物应用调查及耐药性分析[G].2004年全国危重病急救医学学术会议论文集,2004:139-140.
  • 4Smith JL, Fratamico PM. Fluoroquinolone resistance in carnpylohacter [J]. J Food Prot, 2010,73(6) :1141 -1152.
  • 5Pallo - Zimmerman LM, Byron JK, Graves TK. Fluoroquinolones : then and now[J]. Compend Contin Edue Vet, 2010,32(7) :El -9.
  • 6Yamaguchi H, Kawai H, Matsumoto T, et al. Post - marketing surveil- lance of the safety of levofloxacin in Japan [ J ]. Chemotherapy, 2007,53 (2) :85 - 103.
  • 7Altin T,Ozcan O,Turhan S,et al.Torsade de pointes associated with moxifloxacin:a rare but potentially fatal adverse event[J].Can J Cardiol,2007,23(11):907-908.
  • 8Dale KM,Lertsburapa K,Kluger J,et al.Moxifloxacin and torsade de pointes[J].Ann Pharmacother,2007,41(2):336-340.
  • 9Ostrowska K, Strzelczyk A, Rozalski A, et al. Bacteri-al biofilm as a cause of urinary tract infection -pathogens, methods of prevention and eradication. Postepy Hig Med Dosw, 2013, 67(3):1027-1033.
  • 10Smith JL, Fratamico PM. Fluoroquinolone resistance in campylobacter. J Food Prot, 2010, 73(6):1141-1152.

引证文献7

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部